In a randomized, double-blind study of tocilizumab versus placebo conducted in Japan, although the primary endpoint (time to recurrence) did not reach statistical significance between the treatment groups, there was a favorable trend ( 22 ).
← all excerpts
Case Report: Can early full-course tocilizumab therapy reverse vascular stenosis in Takayasu arteritis?
1
—
—